Investigating the Link Between Type 2 Immunity and NAFLD in Human Obesity

Launched by MAYO CLINIC · Jan 15, 2020

Keywords

ClinConnect Summary

This clinical trial is exploring how inflammation in body fat and fat buildup around the liver may affect liver health and insulin resistance in people with obesity. Specifically, the researchers want to understand the connection between type 2 immunity (a part of our immune system) and nonalcoholic fatty liver disease (NAFLD) in individuals who are undergoing gastric bypass surgery.

To be eligible for this study, participants should be between 30 and 70 years old, have a body mass index (BMI) over 40, and have confirmed liver fibrosis (a condition where the liver becomes scarred) of a certain level. Importantly, participants should not have certain conditions like autoimmune diseases, active cancer, or heavy alcohol use. If you choose to take part, you can expect to undergo assessments related to your liver health and inflammation. This research could help improve our understanding of obesity-related liver problems and potentially lead to better treatments in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Undergoing gastric bypass surgery
• • Confirmed AUROC F=0 or F\>2 liver fibrosis
• • Age 30-70 years
• • BMI greater than 40 kg/m2
• • Negative pregnancy test (female only)
• • Lab Values: Normal TSH
• Exclusion Criteria:
• • Autoimmune diseases
• • Hepatitis B or C positive
• • Heavy alcohol use
• • Active smoking history
• • Active cancer history
• • History of asthma
• • History of COPD
• • Taking Plavix or Coumadin
• • Blood donation within past 2 months
• • Glucocorticoid Therapy
• • Taking antihistamine on regular basis